CSIMarket
 


Entera Bio Ltd   (ENTX)
Other Ticker:  
 

Entera Bio Ltd 's Quick Ratio

ENTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Entera Bio Ltd 's Cash & cash equivalent grew by 45.27 % in the IV Quarter 2023 sequentially, while Current Liabilities decreased, this led to improvement in Entera Bio Ltd 's Quick Ratio to 11.51, above Entera Bio Ltd average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 8 other companies have achieved higher Quick Ratio than Entera Bio Ltd in forth quarter 2023. While Quick Ratio total ranking has improved so far during the IV Quarter 2023 to 105, from total ranking in the third quarter 2023 at 734.

Explain Quick Ratio?
How much Cash & cash equivalents ENTX´s has?
What are ENTX´s Current Liabilities?


ENTX Quick Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Change -23.44 % 78.2 % -41.86 % - -
Y / Y Cash & cash equivalent Change -10.48 % -47.04 % -63.3 % - -
Quick Ratio MRQ 11.51 4 5.3 7.39 9.85
ENTX's Total Ranking # 105 # 734 # 673 # 472 # 375
Seq. Current Liabilities Change -49.53 % 9.91 % 19.29 % 15.68 % 17.48 %
Seq. Cash & cash equivalent Change 45.27 % -16.97 % -14.55 % -13.14 % -14.06 %



Quick Ratio forth quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 9
Healthcare Sector # 34
Overall Market # 105


Quick Ratio Statistics
High Average Low
13.46 8.56 4
(Sep 30 2022)   (Sep 30 2023)




Financial Statements
Entera Bio Ltd 's Current Liabilities $ 1 Millions Visit ENTX's Balance sheet
Entera Bio Ltd 's Cash & cash equivalent $ 11 Millions Visit ENTX's Balance sheet
Source of ENTX's Sales Visit ENTX's Sales by Geography


Cumulative Entera Bio Ltd 's Quick Ratio

ENTX's Quick Ratio for the trailling 12 Months

ENTX Quick Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities TTM Growth -23.44 % 78.2 % -41.86 % - -
Y / Y Cash & cash equivalent TTM Growth -10.48 % -47.04 % -63.3 % - -
Quick Ratio TTM 6.38 6.29 8.47 9.25 9.76
Total Ranking TTM # 1640 # 3185 # 549 # 2971 # 3751
Seq. Current Liabilities TTM Growth -49.53 % 9.91 % 19.29 % 15.68 % 17.48 %
Seq. Cash & cash equivalent TTM Growth 45.27 % -16.97 % -14.55 % -13.14 % -14.06 %


On the trailing twelve months basis Current Liabilities decreased faster than Entera Bio Ltd 's average Cash & cash equivalent, this led to increase in in Entera Bio Ltd 's Quick Ratio to 6.38, Quick Ratio remained below ENTX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 41 other companies have achieved higher Quick Ratio than Entera Bio Ltd . While Quick Ratio overall ranking has improved so far to 1640, from total ranking during the twelve months ending third quarter 2023 at 3185.

Explain Quick Ratio?
How much Cash & cash equivalents ENTX´s has?
What are ENTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 42
Healthcare Sector # 329
Within the Market # 1640


trailing twelve months Quick Ratio Statistics
High Average Low
8.65 7.14 5.9
(Mar 31 2023)   (Sep 30 2023)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Biotechnology & Pharmaceuticals Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Enzon Pharmaceuticals inc   27.43 $ 47.012  Millions$ 1.714  Millions
Estrella Immunopharma Inc   22.69 $ 9.046  Millions$ 0.399  Millions
Immunovant Inc   21.73 $ 690.937  Millions$ 31.796  Millions
Elevation Oncology inc   20.05 $ 83.107  Millions$ 4.145  Millions
Compass Therapeutics Inc   19.54 $ 152.461  Millions$ 7.801  Millions
Acumen Pharmaceuticals Inc   18.77 $ 243.522  Millions$ 12.971  Millions
Krystal Biotech Inc   16.08 $ 532.178  Millions$ 33.094  Millions
Denali Therapeutics Inc   13.27 $ 1,034.511  Millions$ 77.982  Millions
Anavex Life Sciences Corp   12.42 $ 143.765  Millions$ 11.578  Millions
Allogene Therapeutics inc   12.10 $ 448.697  Millions$ 37.079  Millions
Replimune Group Inc   12.07 $ 466.351  Millions$ 38.650  Millions
Caribou Biosciences Inc   11.62 $ 328.827  Millions$ 28.302  Millions
Entera Bio Ltd   11.51 $ 11.019  Millions$ 0.957  Millions
Scholar Rock Holding Corp  11.05 $ 279.938  Millions$ 25.333  Millions
Voyager Therapeutics Inc   10.68 $ 230.875  Millions$ 21.627  Millions
Creative Medical Technology Holdings Inc   9.71 $ 3.467  Millions$ 0.357  Millions
Century Therapeutics inc   9.68 $ 172.738  Millions$ 17.846  Millions
Vir Biotechnology Inc   8.70 $ 1,525.824  Millions$ 175.407  Millions
Pharmacyte Biotech Inc   8.12 $ 61.210  Millions$ 7.539  Millions
Passage Bio inc   6.99 $ 114.294  Millions$ 16.341  Millions
Black Diamond Therapeutics Inc   6.69 $ 131.400  Millions$ 19.646  Millions
Fresh Tracks Therapeutics Inc   6.56 $ 10.868  Millions$ 1.656  Millions
Tarsus Pharmaceuticals Inc   6.16 $ 227.442  Millions$ 36.936  Millions
Springworks Therapeutics Inc   6.13 $ 479.202  Millions$ 78.170  Millions
Biontech Se  5.72 $ 13,263.936  Millions$ 2,318.960  Millions
Inhibrx Inc   5.12 $ 277.924  Millions$ 54.249  Millions
Editas Medicine Inc   5.11 $ 323.111  Millions$ 63.217  Millions
Argenx se  4.84 $ 2,048.844  Millions$ 422.993  Millions
Twist Bioscience Corporation  4.77 $ 311.144  Millions$ 65.228  Millions
Molecular Partners Ag  4.67 $ 67.309  Millions$ 14.416  Millions

Date modified: 2024-03-10T17:10:52+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright İ 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com